21st International Congress » Parkinson's Disease: Cognition

Date: Wednesday, June 7, 2017

Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Meeting: 21st International Congress

1:15pm-2:45pm: A new psychosocial intervention for people with Parkinsonian dementias: Adherence, barriers and facilitators

S. McCormick, K. McDonald, S. Vatter, V. Orgeta, E. Poliakoff, S. Smith, M. Silverdale, B. Fu, I. Leroi (Manchester, United Kingdom)

1:15pm-2:45pm: Action Verb Generation as a marker of cognitive function in Parkinson disease

O. Yerokhin, K. Smith (Worcester, MA, USA)

1:15pm-2:45pm: Action Verbal Fluency is Related to the Functional Integrity of the Cognitive Cortico-Striatal Loop in Parkinson’s Disease

N. Auclair-Ouellet, A. Hanganu, E. Mazerolle, J. Sarna, M. Kibreab, J. Cheetham, I. Kathol, A. Haffenden, B. Pike, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Anosognosia for Levododopa-induced Dyskinesias in PD – Frequency

R. Doyle Maia, F. Cardoso, P. Caramelli (Vitória, Brazil)

1:15pm-2:45pm: APOE4+ status increases rate of longitudinal cognitive decline in Parkinson Disease patients with low CSF Aβ42

K. Leaver, T. Hendershott, D. Zhu, L. Tian, K. Poston (Stanford, CA, USA)

1:15pm-2:45pm: Apolipoprotein E ε4 allele frequency in Korean Patients with Parkinson’s disease Dementia

M. Park (Daegu, Republic of Korea)

1:15pm-2:45pm: Apomorphine infusion does not impair cognitive action control in Parkinson’s disease

J. Duprez, J.-F. Houvenaghel, S. Drapier, D. Drapier, M. Vérin, P. Sauleau (Rennes, France)

1:15pm-2:45pm: Association of arterial stiffness with cognition in patients with Lewy body disorder

J.Y. LEE, D.-W. Ryu, J.-S. Kim (Seoul, Republic of Korea)

1:15pm-2:45pm: Cerebrospinal fluid lysosomal enzymes and cognition in Parkinson’s disease

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, P. Martínez-Lage, A. Izagirre, S. Paciotti, L. Parnetti, P. Calabresi, T. Beccari, M. Rodriguez-Oroz (San Sebastián, Spain)

1:15pm-2:45pm: Classification of neurocognitive impairment in Spanish speaking Parkinson’s disease patients

S. Anderson, C. Bermudez, N. Sun-Suslow, L. Segala, H. Moore, C. Singer, J. Jagid, G. Rey, B. Levin (Chicago, IL, USA)

1:15pm-2:45pm: Cognition in the PREDICT-PD Cohort

A. Nagy, E. Hardaker, J. Bestwick, G. Giovannoni, T. Warner, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)

1:15pm-2:45pm: Cognitive data in the Parkinson’s Progression Markers Initiative: Comparison of normative data approaches

K. Wyman-Chick, M. Barrett, P. Martin, C. Manning, S. Sperling (Charlottesville, VA, USA)

1:15pm-2:45pm: Cognitive function and impulsive-compulsive behaviors in Parkinson’s disease motor subtypes

S.-C. Yao, P.-N. Wang, K.-K. Liao, D.-E. Shan (Taipei, Taiwan)

1:15pm-2:45pm: Cognitive strategy use during daily activities in people with Parkinson’s Disease

I. Sturkenboom, E. Steultjens, M. Nott, C. Chapparo (Nijmegen, Netherlands)

1:15pm-2:45pm: Consideration of the relationship between severity of Parkinson’s disease and cognitive function, depression, quality of life

M. Saruwatari, M. Sagawa, A. Kumon, K. Hasegawa (Sagamihara, Japan)

1:15pm-2:45pm: Decision making under uncertainty in medicated and un-medicated Parkinson’s disesase

J. Corrow, M. Cherkasova, A. Taylor, J. Stoessl, M. McKeown, S. Apple Creswell, J. Barton (Vancouver, BC, Canada)

1:15pm-2:45pm: Decisional capacity for Goals of Care in Parkinson’s Disease with Cognitive Concerns

M. Abu Snineh, R. Camicioli, J. Miyasaki (Jerusalen, Israel)

1:15pm-2:45pm: Defective visual perception in patients with Lewy body disease: assessment of hallucinations with pareidolia test.

Y. Higashi, T. Tabuchi, M. Tabata (Himeji, Japan)

1:15pm-2:45pm: Depression and Cognitive Performance in Patients with Parkinson’s Disease

A.J. Jacob, S. OJ, S. K, G. Kumarpillai (Bangalore, India)

1:15pm-2:45pm: Development and validation of an alternative version of the Parkinson’s Disease-Cognitive Rating Scale

R. Fernandez-Bobadilla, S. Martinez-Horta, J. Marin-Lahoz, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Differential peculiarities of cognitive disorders in Parkinson’s disease dementia and Vascular dementia

V. Mykhaylov, I. Zdesenko (Kharkiv, Ukraine)

1:15pm-2:45pm: Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

L. Brown, B. Mohamed, E. Thomas (Cardiff, United Kingdom)

1:15pm-2:45pm: Domain-specific impact of cerebral white matter hyperintensities on Parkinson’s disease cognitive functioning

P. Linortner, S. Chernavsky, T. Hendershott, K. Poston (Palo Alto, CA, USA)

1:15pm-2:45pm: Dopamine replacement influences on postural motor learning in Parkinson disease

S. Paul, G. Olivier, C. Walter, S. Schaefer, L. Dibble (Salt Lake City, UT, USA)

1:15pm-2:45pm: Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration

J.-F. Houvenaghel, S. Drapier, J. Duprez, D. Drapier, M. Vérin (Rennes, France)

1:15pm-2:45pm: Effects of dopaminergic medication on executive function in Parkinson’s disease differs according to the clinical stage

H. Murakami, M. Kezuka, R. Kon, M. Kawamura, K. Ono (Tokyo, Japan)

1:15pm-2:45pm: Effects of education level on motor and non-motor symptoms of Brazilian patients with Parkinson’s disease.

E. Lirani-Silva, R. Vitório, P.C. Santos, C. Teixeira-Arroyo, L. Simieli, N. Conceicao, P. Sousa, L. Gobbi (Rio Claro, Brazil)

1:15pm-2:45pm: Event-related potentials and mild cognitive impairment in Parkinson’s disease.

J. Pagonabarraga, J. Marin-Lahoz, A. Horta, M. Cornella, H. Bejr-Kasem, S. Martinez-Horta, J. Pérez-Pérez, M.Á. Boti, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Extended “Timed Up and Go”: A Clinical Indicator of Cognitive State in Parkinson’s Disease?

T. Evans, A. Jefferson, M. Byrnes, S. Walters, S. Ghosh, F. Mastaglia, B. Power, R. Anderton (Perth, Australia)

1:15pm-2:45pm: Feasibility of utilizing the NIH Toolbox in Parkinson’s disease subjects with deep brain stimulation

J. Emerson, P. Dhruva, C. McLeod, R. Moses-Kessler, L. Metman, G. Pal (Chicago, IL, USA)

1:15pm-2:45pm: Feasibility, tolerability and acceptance of a psychosocial intervention for people with Parkinsonian dementia: The INVEST trial.

S. McCormick, K. McDonald, S. Vatter, V. Orgeta, E. Poliakoff, S. Smith, M. Silverdale, B. Fu, I. Leroi (Manchester, United Kingdom)

1:15pm-2:45pm: Fluency boost from walking in Parkinson’s disease

O. Barthelemy, R. Salazar, S. Neargarder, J. DeGutis, T. Ellis, A. Cronin-Golomb (Boston, MA, USA)

1:15pm-2:45pm: Genetic variations in Amyloid-beta1-42 clearance proteins determine onset of dementia in Parkinson’s disease and dementia with Lewy bodies

K. Brockmann, S. Lerche, A. Apel, A.-K. Hauser, I. Liepelt Scarfone, D. Berg, T. Gasser, C. Schulte, W. Maetzler (Tübingen, Germany)

1:15pm-2:45pm: Ghrelin and the IGF-1 axis in cognitive impairment in PD

F. Johnston, M. Siervo, A. Hornsby, J. Davies, D. Burn (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Global inhibitory control in PD is impaired ON dopaminergic medication but not ON STN-DBS

D. Kübler, H. Schroll, A. Kühn (Berlin, Germany)

1:15pm-2:45pm: Goalkeeper game: a novel test to identify early implicit learning alterations in people with Parkinson’s disease

M.E. Pimentel Piemonte, A. Galves, A. Frazao Helene, M. D'Alencar (Sao Paulo, Brazil)

1:15pm-2:45pm: High systolic blood pressure is associated with cognitive impairment in Parkinson’s disease (PD)

H. Chan, Y. Cheung, T. Fung, A. Leung, W. Fong (Hong Kong, Hong Kong)

1:15pm-2:45pm: Higher risk of cognitive impairment in Parkinson’s disease with comorbid diabetes

P. Schmidt, F. Cubillos, K. Lyons, C. Marras, T. Davis, E. Nelson, M. Okun (Miami, FL, USA)

1:15pm-2:45pm: IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson’s disease patients

G. Dervenoulas, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Implicit memory analysis in patients with Parkinson’s Disease with Deep Brain Stimulation, in ON and OFF stages, using a computerized test battery.

E. Barbosa, H. Charchat-Fichman, J. Santos (Rio de Janeiro, Brazil)

1:15pm-2:45pm: INFLUENCES OF GENDER, DEPRESSION AND DISEASE SEVERITY ON MoCA SUBSCORES IN PARKSINON’S DISEASE

P. Surathi, M. Mirian, K. Sundvick, S. Cresswell, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm: Information Content of Spoken Language in Parkinson’s Disease Without Dementia

A. Roberts, D. Post, S. Gutierrez (Evanston, IL, USA)

1:15pm-2:45pm: Intention Awareness in Parkinson’s Disease

S. Di Costa, E. Barow, C. Moll, U. Hidding, O. Fründt, C. Gerloff, R. Erro, M. Pötter-Nerger, C. Buhmann, P. Haggard, C. Ganos (LONDON, United Kingdom)

1:15pm-2:45pm: Mild cognitive impairment in newly diagnosed Parkinson’s disease: a three year follow up

R. Lawson, A. Yarnall, G. Duncan, D. Breen, T. Khoo, C. Williams-Gray, R. Barker, D. Burn (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Motor imagery increases imitation of hand movements in Parkinson’s disease

J. Bek, E. Gowen, S. Vogt, T. Crawford, E. Poliakoff (Manchester, United Kingdom)

1:15pm-2:45pm: Motor resonance in Parkinson’s disease: Effects of observed actions on behaviour

E. Poliakoff, J. Bek, S. Vogt, T. Crawford, E. Gowen (Manchester, United Kingdom)

1:15pm-2:45pm: Multimodal biomarkers as predictors of cognitive decline in Parkinson’s Disease

T. Tropea, J. Berlyand, J. McBride, J. Doshi, C. Davatzikos, L. Shaw, S. Xie, J. Trojanowski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)

1:15pm-2:45pm: Neurodegenerative biomarker abnormality frequency in idiopathic REM sleep behavior disorder

A. Boeve, S. McCord, P. Timm, D. Sandness, N. Commers, E. Duwell, G. Tabatabai, S. McCarter, M. Junna, M. Lipford, M. Tippmann-Peikert, B. Boeve, M. Silber, E. St. Louis (Rochester, MN, USA)

1:15pm-2:45pm: Oscillatory dynamics of impaired novelty detection at early Parkinson’s disease

R. Solis-Vivanco, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico City, Mexico)

1:15pm-2:45pm: Patient-reported hallucinations and the probability of progression to dementia in Parkinson’s disease

K.-L. Horne, D. Myall, M. MacAskill, L. Livingston, S. Grenfell, T. Melzer, T. Pitcher, T. Anderson, J. Dalrymple-Alford (Christchurch, New Zealand)

1:15pm-2:45pm: Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

G. Pagano, T. Yousaf,, C. Loane, S. Polychronis, H. Wilson, B. Giordano, F. Niccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Predict cognitive decline with non-clinical markers in Parkinson’s disease

T. Yousaf, G. Pagano, F. NIccolini, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Prediction of cognitive progression in Parkinson’s disease using three cognitive screening measures

C. Nazor, C. Zabetian, C. Johnson, B. Fish, J. Quinn, K. Chung, A. Peterson-Hiller, S.-C. Hu, T. Montine, J. Leverenz, K. Edwards, B. Cholerton (Seattle, WA, USA)

1:15pm-2:45pm: Predictor of progressive mild cognitive impairment in patients with Parkinson’s disease.

Y. Tajiri, K. Wada-Isoe, M. Hamada, M. Sawada, K. Nakashima (Yonago, Japan)

1:15pm-2:45pm: Pro-saccades predict decline in attention over 18months in newly diagnosed Parkinson’s disease

S. Stuart, L. Alcock, J. Nell, R. Lawson, R. Morris, A. Yarnall, D. Burn, L. Rochester (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Prospective longitudinal CSF measurements and cognitive decline in GBA-associated Parkinsonism: not Abeta or Tau but Lewy body pathology?

S. Lerche, C. Schulte, K. Srulijes, A. Pilotto, T. Rattay, A.-K. Hauser, E. Stransky, C. Deuschle, I. Csoti, H. Zetterberg, I. Liepelt-Scarfone, T. Gasser, W. Maetzler, D. Berg, K. Brockmann (Tübingen, Germany)

1:15pm-2:45pm: Quantifying reinforcement learning deficits in early stage Parkinson’s patients using a strategic decision-making task

A. Parr, B. Coe, S. Murdison, G. Pari, D. Munoz (Kingston, ON, Canada)

1:15pm-2:45pm: Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson’s disease

H. Sawada, S. Orimo, A. Inaba, M. Takahashi (Tokyo, Japan)

1:15pm-2:45pm: Relationship between Insulin-like Growth Factor-1 and characteristics of physical activity in patients with Parkinson’s disease

K. Nagaki, M. Ikenaga, S. Fujioka, Y. Tsuboi (fukuoka, Japan)

1:15pm-2:45pm: Risk Factors for Dementia in Parkinson’s disease

M.I. Khalil, M.R. Rahman, S. Munira (Dhaka, Bangladesh)

1:15pm-2:45pm: Self-awareness of cognitive functions in Parkinson’s disease patients with and without mild cognitive impairment.

M. Hoock, F. Maier, R. Kaur, C. Eggers, L. Timmermann (Cologne, Germany)

1:15pm-2:45pm: Sleep architecture in Parkinson´s disease and Parkinson’s disease associated dementia

L. Sousa, I. Laranjinha, J. Lopes, J. Ramalheira, A.M. da Silva, A.B. Lima, M. Magalhães (Porto, Portugal)

1:15pm-2:45pm: Stabile cognitive profile one year after subthalamic nucleus deep brain stimulation in patients with advanced Parkinson’s disease

T. Remšak, A. Bujisić, S. Šešok, S. Brezovar, A. Pražnikar, M. Kramberger, D. Georgiev, D. Flisar, K. Boetzel, J. Mehrkens, M. Benedičič, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

1:15pm-2:45pm: Subcortical involvement in body and mental action processing: an electrophysiological registration study

M. De Letter, P. Santens, D. Van Roost, G. Strobbe, P. Van Mierlo, A. Aerts, A. Bruggeman, K. De Keyser (Ghent, Belgium)

1:15pm-2:45pm: Subcortical involvement in phonological input processing: an electrophysiological registration study

A. Bruggeman, K. De Keyser, A. Aerts, P. Van Mierlo, G. Strobbe, D. Van Roost, P. Santens, M. De Letter (Ghent, Belgium)

1:15pm-2:45pm: Subjective cognitive complaints in Parkinson’s disease patients: what should we value ?

R. Barbosa, M. Mendonça, T. Lampreia, R. Miguel, A. Caetano, P. Bugalho (Lisbon, Portugal)

1:15pm-2:45pm: Subjective cognitive decline reflects recent cognitive change in non-demented patients with Parkinson’s disease

J.Y. Hong, Y. Lee, M. Sunwoo, Y. Sohn, P.H. Lee (Wonju, Republic of Korea)

1:15pm-2:45pm: Tau predicts cognitive impairment in a prospective longitudinal CSF study in Parkinson’s Disease

S. Lerche, I. Wurster, O. Hanson, B. Roeben, C. Schulte, T. Gasser, H. Zetterberg, D. Berg, W. Maetzler, K. Brockmann (Tuebingen, Germany)

1:15pm-2:45pm: The association between motor laterality and cognitive impairment in Parkinson’s disease

J.S. Kim, J.W. Cho, J. Youn (Seoul, Republic of Korea)

1:15pm-2:45pm: The Cats & Dogs Test: a web-based platform to detect early visual processing deficits in Parkinson’s disease

R. Weil, B. Bahrami, D. Schwarzkopf, I. Pavisic, K. Pappa, R. Schade, H. Morris (London, United Kingdom)

1:15pm-2:45pm: The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients

I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, K. Brockmann, T. Gasser, S. Becker, J. Streffer, D. Berg (Tübingen, Germany)

1:15pm-2:45pm: The Effect of Anxiety on Cognition in Parkinson’s Disease

S. Anderson, G. Stebbins, B. Bernard, A. Negron, J. Goldman (Chicago, IL, USA)

1:15pm-2:45pm: The Effects of Contingency-based Musical Gait Feedback on Cognition in Individuals with Parkinson’s disease: An Interim Analysis

J. Burt, E. Ravid, S. Bradford, N. Fisher, Y. Zeng, B. Hu, R. Camicioli (Edmonton, AB, Canada)

1:15pm-2:45pm: The Impact of Cognitive Changes on Everyday Life for People with Parkinson’s: The Patient’s Perspective

J. Wertheimer, A. Gottuso, A. Duboille, M. Tuchman, C. Walton (Los Angeles, CA, USA)

1:15pm-2:45pm: The value of classical cerebrospinal fluid protein ratios and peripheral inflammation in Parkinson’s disease cognitive impairment

M. Delgado-Alvarado, R. Dacosta-Aguayo, I. Navalpotro-Gómez, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergareche, J. Martí-Massó, M. Rodríguez-Oroz (San Sebastián, Spain)

1:15pm-2:45pm: Use of latent class analysis and growth mixture modeling to examine longitudinal neurocognitive trajectories in non-demented Parkinson’s disease

L. Brennan, K. Devlin, D. Mechanic-Hamilton, J. Rick, S. Xie, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J. Duda, J. Morley, R. Akhtar, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

1:15pm-2:45pm: Validation of a performance-based assessment of functional ability related to cognition in Parkinson’s disease

S. Holden, L. Medina, B. Hoyt, S. Sillau, J. Goldman, D. Weintraub, B. Kluger (Aurora, CO, USA)

1:15pm-2:45pm: Validation of Computerised Measures of Executive Functioning for use in Parkinson’s Disease Assessments.

T. Dominey, C. Carroll, R. Noad, C. Newman, S. Hall (Plymouth, United Kingdom)

1:15pm-2:45pm: Variation in Longevity Gene KLOTHO Associates with Measures of Resilience Against Parkinson’s Disease

N. Luthra, J. Ostrem, D. Dubal (San Francisco, CA, USA)

1:15pm-2:45pm: White matter microstructural damage as predictor of cognitive decline in Parkinson’s disease

T. Stojkovic, E. Stefanova, F. Agosta, S. Galantucci, I. Stankovic, V. Markovic, E. Canu, M. Copetti, M. Filippi, V. Kostic (Belgrade, Serbia)

« View all sessions from the 21st International Congress.